The VICTOR study showed comparable efficacy of treatment with intravenous ganciclovir and oral valganciclovir for cytomegalovirus (CMV) disease in solid organ transplant recipients. Oral therapy is now recommended treatment in clinical practice and guidelines. The VICTOR biobank was used in a series of post hoc analyses that yielded unique and clinically valuable insights into CMV treatment and pathogenesis. For example, the importance of tailoring therapy to initial viral load, the effect of immunosuppression on outcomes, and the need to continue therapy until undetectable viral load to prevent recurrence and emergence of resistant strains. Data were also used to validate the use of international units (IU) in quantitative measurements of CMV DNAemia, which may help future studies to define relevant cutoffs for treatment guidance. The analyses also showed the importance of inflammation on viral outcomes and identified potential targets for future studies. Here we summarize the valuable lessons learned from analysis of the VICTOR data set and sample repository.
Modern immunosuppression has greatly improved outcomes in solid organ transplant recipients during the last 4 decades. However, transplant recipients are at increased risk of infection as well as premature cardiovascular disease and malignancy. One of the most important infections in this setting is cytomegalovirus (CMV) infection, which is common and associated with significant morbid effects and occasional deaths in this population. In addition to acute complications, persistent CMV replication, even at a low level, could contribute to other complications such as cardiovascular disease [1] . Treatment of CMV infection has been difficult in the past, requiring intravenous treatment with ganciclovir for prolonged periods. The development of ganciclovir's prodrug, valganciclovir, with 10-fold greater oral bioavailability, offered the possibility of oral and more simplified therapy.
To establish the comparative efficacy and safety of valganciclovir for treatment for CMV disease we designed an investigatorinitiated study in solid organ transplant recipients: the VICTOR trial [2] . This is one of the few large-scale investigator-initiated randomized trials in organ transplantation and one of even fewer to address end points other than acute rejection and graft survival. Children and patients with life-threatening CMV disease were not included. About three-quarters of the study population were kidney transplant recipients and the rest were relatively evenly distributed among liver, heart, and lung transplants. The study established that oral valganciclovir is noninferior to intravenous therapy, a finding that has had direct clinical impact and is now adopted in clinical guidelines [3] [4] [5] . The relatively low number of nonkidney transplants is a limiting factor, and extrapolation to patients with low representation in the study should be made with caution. In addition, because the treatment schedule was fixed for all patients, the results can only provide indices of alternative treatment strategies, for example, treating until results are negative for viremia or targeting ganciclovir or valganciclovir with therapeutic drug monitoring. A significant strength of VICTOR is that a biobank of samples was established and combined with the well-characterized clinical database. Under the control of the VICTOR steering committee, the data were used to pursue indicative and hypothesis generating, post hoc analyses. In this article, we describe and discuss the implications of the 16 peer-reviewed publications that have come from VICTOR. The post hoc analyses performed which were not predefined secondary end points, focused on (1) immunosuppressive load [6] , (2) genetic polymorphisms [7] [8] [9] , (3) microRNAs (miRNAs) [10, 11] , (4) viral load polymerase chain reaction (PCR) assays [12, 13] and (5) plasma biomarkers [14] [15] [16] [17] .
The study protocol has been described elsewhere [2, 18] . Briefly, the VICTOR study recruited solid organ transplant recipients with proven CMV disease. In this prospective, open study, patients were randomized to 21 days of intravenous ganciclovir or oral valganciclovir, followed by 4 weeks of once-daily valganciclovir secondary prophylaxis. Patients were followed for 1 year. The primary end point was noninferiority of oral valganciclovir in the eradication of CMV after 21 days of treatment (central laboratory analyses). The study fulfilled the criteria for noninferiority and showed superimposable DNAemia eradication curves.
DNAemia eradication rates, CMV-related disease recurrence, development of resistance and tolerability were comparable between the treatment groups [2, 18] . The clear "take home" message from this study, that patients who are able to take oral therapy are as effectively treated with either oral valganciclovir or intravenous ganciclovir, has led to the adoption of oral therapy for CMV disease in most centers worldwide and is recommended in the recent International CMV consensus guidelines [4] .
FACTORS INFLUENCING TREATMENT EFFICACY
Having established comparable efficacy of the treatment arms we sought to identify common factors that influence the treatment in pooled data from all patients. To compare the effects from the different substudies, we reanalyzed all data ( Table 1) .
Clearance of CMV is dependent on the hosts' immune response. Immune monitoring strategies were not well developed when VICTOR was designed, and appropriate samples for this type of analyses were not obtained. However, we were able to study the influence of immunosuppressive load [6] . Patients with dual versus triple immunosuppressive therapy and those with lower blood concentrations of calcineurin inhibitors had significantly improved and more rapid CMV DNA eradication (Table 1) .
Viral infections, such as CMV infection, induce an inflammatory response in the host. Although this immune activation may be beneficial contributing to viral suppression, it may also promote CMV replication, delay virus eradication, and increase the risk of disease recurrence, potentially representing a vicious circle. We therefore assessed different plasma markers of inflammation and endothelial cell activation. Baseline levels of the chemokine CXCL16, C-reactive protein (CRP), pentraxin 3 (PTX3; belonging to the pentraxin family that also includes CRP), von Willebrand factor (vWF; endothelial-related inflammation), and osteoprotegrin (OPG; a member of the tumor necrosis family [TNF] receptor superfamily) were independently associated with virological and clinical outcomes [14, 16] . Levels of vWF at day 21 were also associated with recurrence. This suggests that the presence of active inflammation-irrespective of its cause-affects the response to antiviral therapy and suggest the need for prolonged treatment.
We also investigated several factors more directly linked to the virus. The most significant factor predicting treatment success after 3 weeks of treatment was baseline viral load ( Figure 1 ) [2] . Persistent DNAemia after 3 weeks was also a significant risk factor for recurrence [18] . These observations are intuitively obvious. The higher the initial viral load, the longer it will take to eradicate and the more likely it will be that short-term treatment will be ineffective. From the viewpoint of the treating clinician, there is an important message: the 21-day treatment regimen is not "one size fits all," and with higher baseline viral loads the need for a longer treatment phase can be expected. Moreover, one should aim for undetectable viral titer before moving to prophylaxis, to minimize the risk of recurrence, but should be alert for alternative reasons for noneradication, for example, development of ganciclovir resistance.
There is genetic variation in CMV that contributes to resistance, specifically in the UL54 and UL97 genes [22] . The incidence of ganciclovir resistance was low (3%), with no difference between groups (P = .51). Presence of resistance mutations significantly increased the risk of eradication failure at both day 21 (odds ratio [OR], 11.04; P = .02) and day 49 (6.82; P = .001). In addition, ganciclovir resistance at any time between baseline and day 49 was significantly associated with persistent DNAemia at day 21 (OR, 11.83; P = .02). Moreover, UL97 mutants that conferred ganciclovir resistance had significantly longer half-lives than wild-type strains, polymorphic variants, and strains with mutations of unknown significance (P = .045). These resistance data underscore that prolonged antiviral therapy may be required, particularly in patients with high baseline viral load, before moving to secondary prophylaxis. Testing for ganciclovir resistance should also be considered, however, when CMV eradication takes longer than anticipated.
We also analyzed CMV isolates for variation in glycoprotein B (gB), glycoprotein N (gN), and immediate early-1 genes [8, 9] . Polymorphisms in the gB gene allow discrimination of 4 distinct genotypes (gB1-4). Half of the patients had mixed infection with ≥2 strains (Figure 2 ). Donor CMV + (D + )/recipient CMV + (R + ) patients were more likely to have mixed gB infection than D + /R − (40% vs 12%; P < .001). Median baseline viral loads were higher and the time to viral eradication was longer (P = .005 and P = .03, respectively) for mixed infections, an independent predictor of failure to eradicate DNAemia after 3 weeks (OR, 2.66; 95% confidence interval, 1.31-5.38; P = .007). However, no effect of individual gB genotypes on recurrence was seen. From a clinical viewpoint, screening for viral genotypes may add some information regarding complexity in addition to information provided by baseline viral load. This would be of greatest relevance in D + /R + patients.
In a more detailed analysis of viral clearance kinetics [7] , the first-phase rapid decline in viral load was dependent on gB for cytokine levels were estimated with pROC [20] , and ORs (exposed vs unexposed) and 95% CIs were estimated with epiR [21] . P values denote significance for comparisons with an OR of 1.00. HOR load is the P value from the test of the HOR stratified by viral load at baseline, with a cutoff of 10 3 copies/mL; HOR treatment, the P value from the test of the HOR stratified by initial treatment (ganciclovir or valganciclovir). b CMV eradication faster with lower immunosuppressive load.
c P value for the factor at the binary logistic regression.
d P value for the interaction at the binary logistic regression.
e Deviation from homogeneity denotes an imbalance of distribution of the 2 factors (early eradication and high calcineurin level) across strata of baseline viral load; however, viral load and high calcineurin inhibitor level (P = .02) remained independently significant without evidence of significant interaction. f Frequency of resistance at onset: 3% of patients.
g gB of mixed types was found in 50% of the samples; gB type 1 was found in 25% of the samples, and gB types 2, 3, and 4 were found in the balance.
h Deviation from homogeneity denotes an imbalance of distribution of the 2 factors (serostatus and mixed gB infection) across strata of viral load; however, in both cases serostatus remained significant (P < .001 after adjustment) while viral load remained not significant. i IE1 of mixed types was found in 15.8% of the valid samples.
j gN of mixed types was found in 21.9% of the valid samples.
k Deviation from homogeneity denotes an imbalance of distribution of the 2 factors (vWF ≥ 48.0 AU at baseline and persistent clinical symptoms) across strata of initial treatment; however, vWF remained significant (P = .001 after adjustment), while initial treatment remained not significant.
genotype, whereas the viral load reduction after 3 weeks was relatively insensitive. A strong correlation was observed between first-phase decline and the extent of viral load reduction after 3 weeks treatment. Viral gN and immediate early-1 are key viral genes and important immune targets. However, no single genotype of gN or immediate early-1 was strongly associated with outcome. Mixed infection was present in 21.9% and 15.8%, respectively. As for gB, D + /R + patients had multiple strain infections more frequently and exhibited delayed viral clearance (P = .03). They also had higher rates of virological recurrence (P = .008), which was not seen with mixed gB infections. Many patients with CMV disease have coinfection with other herpesviruses, such as human herpesvirus (HHV) 6 and HHV-7. A detailed analysis was performed of the prevalence of HHV-6/7 DNAemia [23] . Baseline viremia was found in 9% and 7%, respectively. The prevalence increased to 31% and 29%, respectively, when infections at any time were included. Baseline CMV loads were similar in patients with and those without HHV-6/7 coinfection, as were the time to CMV eradication and the risk of recurrence. Ganciclovir and valganciclovir treatment were both associated with an initial decline in HHV-6/7 load but did not influence viremia at later time points. Whether other herpesviruses have an important pathological role in transplant recipients is not clear, but the effects of ganciclovir in the early phase may be a hidden benefit of treating CMV infection, and of prophylaxis,.
Post hoc analyses from a prospectively designed study such as the VICTOR study are limited when it comes to determining how best to treat patients with CMV disease. Some treatment guides are summarized in Figure 3 , however, based on the combined results of all VICTOR analyses.
PATHOGENESIS OF CMV INFECTION AND DISEASE
In immunocompromised hosts the main site of CMV replication is in the vascular endothelial cells. To better understand the interaction between infected endothelial cells, leukocyte subtypes and inflammation; we screened for plasma markers of inflammation (CRP, PTX3, soluble TNF receptor 1 [sTNF-R1]), endothelial cell activation (vWF and OPG), and a range of chemokines (RANTES/CCL5, CCL21, CXCL16, and interferon γ-inducible protein 10 [IP-10]/CXCL10).
An interesting feature with the VICTOR trial, because inclusion was based on local viremia measurements, was that 62 patients were baseline DNAemia negative when analyzed centrally. This is a unique group for elucidation of pathogenic patterns in CMV infection, but it is of course limited by the small sample size. There was an association between high levels of sTNF-R1, IP-10, and CCL21 and detectable CMV DNAemia at baseline [14, 15] . The association with IP-10 may be of particular interest, because IP-10 is of major importance for the recruitment of T-helper cells to inflammatory sites [24] . Reprinted from Razonable et al [13] .
There was no association between CMV load and tissue invasive disease in our study; this may reflect clinical practice and the reluctance to obtain biopsy evidence of CMV infection. However, high levels of CRP, PTX3, sTNF-R1, and CCL21 were independently associated with clinical manifestations [15] , raising the possibility that invasive disease-severe enough to warrant a biopsy-is not merely caused by increased CMV replication but may also involve maladaptive immune responses and inflammation. Whereas CRP is produced in the liver, PTX3 is expressed under inflammatory stimuli in endothelial cells, neutrophils, dendritic cells and macrophages [25] . Its relation to tissue-invasive CMV disease may reflect its ability to mirror important local inflammatory responses and tissue damage. The chemokine CCL21 is involved in inflammatory responses and T-cell homing [26] . Our findings suggest a link between clinical manifestations of CMV disease and CRP, PTX3, sTNF-R1, and CCL21 levels, although whether this is specific or part of the wider inflammatory process requires further study.
Both vWF and OPG are markers of endothelial cell activation and vascular inflammation. We observed a strong correlation between OPG and other endothelial cell-secreted factors (vWF and PTX3). This may reflect the ability of OPG and vWF to mirror, or perhaps promote, vascular inflammation and remodeling [16] . Again, whether this is specific, and a potential target to limit the impact of CMV infection, or simply part of inflammation is unknown.
CMV replication is regulated by both intracellular and extracellular host factors. Wingless-related integration site (Wnt) signaling was studied in the VICTOR samples because it has been shown to affect CMV replication in different cell types [27] [28] [29] . Secreted proteins, such as Dickkopf 1 (DKK-1) and secreted frizzled related protein 3, are Wnt signaling antagonists. DKK-1 concentrations were significantly lower in patients with detectable DNAemia [17] . Low levels of DKK-1 and increased levels of secreted frizzled related protein 3 were associated with poor virological outcomes. The findings suggest a role for dysregulated Wnt signaling in CMV pathogenesis (Table 2) .
Other viral factors that have been assessed include CMV miRNAs [30] . CMV encodes multiple miRNAs that regulate both viral and cellular gene expression [31] . In vitro, several CMV miRNAs have been found to down-regulate viral replication [32] . In an analysis of VICTOR samples, several CMV miRNAs were readily detectable [10, 11] . Our data did not support an inhibitory effect of any miRNA. Instead, the expression levels generally correlated with DNA viral load, and the absence of viral miRNA was associated with faster viral clearance. However, we did observe a novel association between hcmv-miR-UL22A-5p and recurrence of CMV viremia, suggesting a potential immunoregulatory role [11] . A detailed set of follow-up experiments suggested a combination of direct mRNA targeting by the miRNA and indirect modulation of gene expression involving isoforms of the transcriptional regulator C-MYC. This supports a broad regulatory potential of CMV over host gene expression. These data corroborate the existence of other yet unexplored roles for CMV miRNAs in viral pathogenesis.
DIAGNOSTICS
PCR has become the standard method for monitoring CMV infections. A common clinical question is the duration of antiviral therapy required to avoid recurrence. The guidelines for the management of CMV viremia in solid organ transplant recipients recommend continuation of treatment until viremia is undetectable [4] . In VICTOR, arbitrary induction and consolidation treatment phases of 3 and 4 weeks were used. CMV loads were measured in plasma samples and provide strong evidence to support current clinical guidelines, because the only predictor of virological (OR, 5.6; P < .001) or clinical (3.90; P < .01) recurrence was failure to eradicate viremia at the end of treatment (day 21) [18] . We also compared 2 quantitative PCR assays in paired plasma and whole-blood samples. In plasma, only free virus is detected, whereas both free and intracellular virus in leukocytes is measured in whole-blood. Plasma viral loads were measured with a commercial quantitative assay (Amplicor; Roche). The limits of quantification and detection, respectively, were 600 and 200 DNA copies/mL. The viral load in whole blood was performed using an "in-house" assay, with lower limits of quantification and detection of 500 and 50 DNA copies/mL, respectively [12] . The initial plasma and whole-blood median viral loads were 17 950 and 118 950 copies/mL, respectively. However, there was a good correlation between the assays (r 2 = 0.7946; P < .001). The whole-blood assay showed greater sensitivity for detection of residual viremia at the end of the treatment period. Undetectable whole-blood viral loads (<50 copies/mL) were achieved by almost 30% at day 21, whereas >50% had clearance of viremia (<200 copies/ mL in plasma; P < .001). Persistent versus negative plasma viral load at day 21 was a significant predictor of recurrence (41.9% vs 23.4% [P = .01]). The same relation was not seen with whole blood viral loads (36.3% vs 23.2% [P = .12]) [12] . The current recommendation to treat until results are negative for DNAemia [4] is based on these data, but an exact cutoff has not yet been validated. The incidence of CMV disease recurrence in patients with plasma viremia at day 21 was 17.2%, compared with 8.2% in those without plasma viremia (P = .08). The incidence of CMV disease recurrence in patients with whole-blood viremia at day 21 was 15.1%, compared with 6.3% in those with negative whole-blood results (P = .12). These data suggest that when monitoring therapeutic response, enhanced sensitivity detection of viremia at the end of treatment is not necessarily advantageous [12] .
Despite the suggested role of viral load monitoring in CMV disease, there is a lack of well-defined thresholds to guide clinicians [4] . The first World Health Organization international standard for human cytomegalovirus for nucleic acid amplification techniques, The National institute for biological standards and control code 09/162, was released for standardization of nucleic acid amplification tests in 2010. When this standard was introduced, stored VICTOR samples were retested, allowing for a unique clinical validation of the new international standard unit [13] . Of 212 patient baseline samples, CMV was detected in 191 samples with a median viral load of 8318 IU/mL (range, 68-43 652 IU/mL). The take-home message is that high viral load at diagnosis mandates longer treatment, and it is essential to confirm undetectable viral levels before stopping therapy.
CONCLUSION
The "headline" results from the VICTOR study are straightforward: intravenous and oral therapies are comparable, at least in patients who are able to absorb oral medication. For clinicians and healthcare providers, the implications are similarly straightforward: patients can be readily treated as outpatients, with oral therapy, with considerable benefits to both patients and healthcare funders. The study provides no information on effects in children or patients with life-threatening or severe gastrointestinal CMV disease. Despite these limitations, it is plausible that the efficacy may be maintained with oral treatment as long as enteral drugs can be administered and no malabsorption is suspected. Measuring plasma concentrations of ganciclovir will be helpful in these cases.
The post hoc analyses have identified a spectrum of secondary issues, some intuitive and some innovative. For the practicing clinician, there are a few important messages, identified or reinforced by VICTOR results. The first is that it is important to measure viral load at the outset and before stopping therapy; the second is that the treatment regimen should be individualized according to DNAemia, and that screening for mutations is necessary only for patients whose PCR levels do not follow the predicted course. Finally, effective treatment is essential to prevent emergence of resistant strains, and modification of immunosuppression has a role in treatment.
The exploratory analyses have shown the importance of a variety of markers of inflammation and their association with the severity of disease and viral outcomes. These relationships require further study but may identify targets to limit the impact of severe disease. We have also shown the impact of viral genotypes on outcomes that, though not essential for clinical practice, may be important as viral resistance increases. We also were able to elucidate several unique aspects of the pathogenesis of CMV reactivation and disease after transplantation. Most importantly, these analyses show the potential benefits of large-scale studies, including detailed biobank samples in transplantation, mirroring findings in other populations, most importantly in the cardiovascular field, and the potential benefits of collaborative international studies. 
